Customs Clearance is the Biggest Challenge for Pharma Cool Chain in Russia & CIS
According to Frost and Sullivan the Russian pharma market expected to be worth $37.15bn in 2016. As the region prepares for a significant growth phase, the article "Russia: Needs to Invest in Cold Chain Infrastructure for Biopharma to Grow" examined the need for capitalise on this interest from big players within the pharmaceutical by investing in its cold chain infrastructure – an asset which will become ever more important as biopharmaceuticals develop. Pharma IQ looked at how companies speci...
To continue reading this story get free access